# Takeda to build 100 billion yen plasma-derived therapy plant in Osaka, Japan

Takeda announced a long-term investment of approximately 100 billion yen to build a new plasma-derived therapy manufacturing facility at its Osaka plant in Juso, Japan. The facility will have a plasma processing capacity of over 2 million liters per year and is expected to start operations around 2030.

- Type: New facility
- Announced: 2023-03-23
- Where: Osaka, Juso, Japan
- Value: $750.0M (100.0B JPY)
- Starts operating: 2030
- Status: announced
- Capacity: 2 million liters per year
- Products: plasma-derived therapies
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Takeda](https://endata.com/companies/52956.md)

## Sources

- [takeda.com](https://www.takeda.com/jp/newsroom/newsreleases/2023/20230323_8373/), 2023-03-23: "当社は、日本の大阪・十三に血漿分画製剤の新製造施設を建設するため、1,000億円規模の長期投資を行うことを決定しましたので、お知らせします。"
- [takeda.com](https://www.takeda.com/newsroom/newsreleases/2023/takeda-to-invest-100-billion-jpy-in-new-pdt-manufacturing-facility/), 2023-03-23: "This investment reflects Takeda’s values-based approach of putting patients first and delivering on its commitments across the company’s patient, people and planet imperatives."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.